Systematic review and meta-analysis of the efficacy and effectiveness of pneumococcal vaccines in adults
JL Farrar, L Childs, M Ouattara, F Akhter, A Britton… - Pathogens, 2023 - mdpi.com
New pneumococcal conjugate vaccines (PCVs), 15-and 20-valent (PCV15 and PCV20),
have been licensed for use among US adults based on safety and immunogenicity data …
have been licensed for use among US adults based on safety and immunogenicity data …
[HTML][HTML] Follow-Up Study of Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against All-Type and Serotype-Specific Invasive Pneumococcal …
KF Nielsen, LB Nielsen, T Dalby… - Emerging Infectious …, 2024 - ncbi.nlm.nih.gov
As a follow-up to a previous study, we investigated vaccine effectiveness (VE) of 23-valent
pneumococcal polysaccharide vaccine (PPSV23) against invasive pneumococcal disease …
pneumococcal polysaccharide vaccine (PPSV23) against invasive pneumococcal disease …
Real-world effectiveness of pneumococcal vaccination in older adults: Cohort study using the UK Clinical Practice Research Datalink
Background The 23-valent pneumococcal polysaccharide vaccine (PPV23) is
recommended for UK older adults, but how age moderates effectiveness is unclear. Methods …
recommended for UK older adults, but how age moderates effectiveness is unclear. Methods …
Decrease of pneumococcal Community-acquired pneumonia hospitalization and associated Complications in children after the Implementation of the 13-valent …
CF Shen, JL Chen, CC Su, WL Lin, ML Hsieh, CC Liu… - Vaccines, 2021 - mdpi.com
The impact of the 13-valent pneumococcal conjugate vaccine (PCV13) on overall
community-acquired pneumonia (CAP) and disease severity still needs thorough evaluation …
community-acquired pneumonia (CAP) and disease severity still needs thorough evaluation …
Pneumococcal Vaccination in Adults: A Narrative Review of Considerations for Individualized Decision-Making
KC See - Vaccines, 2023 - mdpi.com
Pneumococcal disease remains one of the major causes of severe disease in both children
and adults. Severe disease may be prevented by pneumococcal polysaccharide and …
and adults. Severe disease may be prevented by pneumococcal polysaccharide and …
Response to Igarashi, et al, cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of …
KA Feemster, Y Kim, M Abe, K Johnson… - Expert Review of …, 2022 - Taylor & Francis
Igarashi, et al [1]. For the selection of currently available vaccines for use in adult national
immunization programs, cost-effectiveness is an important consideration. Under the base …
immunization programs, cost-effectiveness is an important consideration. Under the base …
Efficacy and effectiveness of pneumococcal vaccination in adults–a second update of the literature. The review is a collaboration between Public Health Institutes in …
B Askeland Winje, JD Berild, DF Vestrheim… - 2022 - fhi.brage.unit.no
Introduction Young children, elderly and persons with weakened immune systems are at
high risk of acquiring invasive pneumococcal disease and pneumococcal pneumonia. Two …
high risk of acquiring invasive pneumococcal disease and pneumococcal pneumonia. Two …
[PDF][PDF] Yttrande över Pneumokockvaccination som ett särskilt vaccinationsprogram för personer 75 år och äldre
EW Ehlin - uppsala.se
Sedan år 2013 regleras nationella vaccinationsprogram genom smittskyddslagen.
Regeringen fattar beslut om vilka sjukdomar som ska omfattas av nationella …
Regeringen fattar beslut om vilka sjukdomar som ska omfattas av nationella …
[引用][C] Yttrande över remiss-Pneumokockvaccination som ett särskilt vaccinationsprogram för personer 75 år och äldre
S Stockholm, MR Östlund